---
title: "LB Pharmaceuticals Inc (LBRX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LBRX.US.md"
symbol: "LBRX.US"
name: "LB Pharmaceuticals Inc"
industry: "Pharmaceuticals"
datetime: "2026-05-20T07:08:25.173Z"
locales:
  - [en](https://longbridge.com/en/quote/LBRX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LBRX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LBRX.US.md)
---

# LB Pharmaceuticals Inc (LBRX.US)

## Company Overview

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [lbpharma.us](https://lbpharma.us) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -20.07 | 209 | - | - | - |
| PB | 2.06 | 92 | 2.40 | 2.15 | 1.62 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-17T04:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 83% |
| Overweight | 1 | 17% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 27.27 |
| Highest Target | 78.00 |
| Lowest Target | 34.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/LBRX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/LBRX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/LBRX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/LBRX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**